Pemphigus Vulgaris Therapeutics Market: Market Size & Forecast 2026

Pemphigus vulgaris is a rare autoimmune disorder characterized by blistering of the skin and mucous membranes, requiring long-term immunosuppressive therapy. The global PV therapeutics market was valued at approximately USD 530-577 million in 2025 and is expected to reach roughly USD 595-1,120 million by 2026-2032, depending on market scope definitions that may include broader supportive-care expenditures. Growth projections vary across research firms, with a consensus CAGR of 7-10% through the early 2030s.

• •Market size estimates for 2026 range from approximately USD 327 million to USD 596 million across different research databases, reflecting differing scope definitions (narrow therapeutics-only vs. broader disease-market approaches)
• •Consensus CAGR is approximately 8.4% (with some sources citing 7.3%), projecting the market to approach or exceed USD 1 billion by the early 2030s
• •The European PV treatment segment alone was valued at roughly USD 106 million in 2024 and is expected to reach approximately USD 169 million by 2030

The primary growth catalyst is the increasing global prevalence of pemphigus vulgaris, which some estimates place at 0.5-3.2 cases per 100,000 people annually, driven by improved diagnostic awareness and disease recognition among clinicians. The widespread off-label adoption of rituximab, originally developed for lymphoma, has significantly expanded the treatable patient population and established a biologic treatment paradigm. Additionally, the chronic, relapsing nature of PV creates sustained demand for long-term therapy, while an emerging pipeline of targeted agents promises to further broaden treatment options.

• •Improved diagnostic awareness and clinical recognition are expanding the identified patient pool, particularly in developing regions where PV was historically underdiagnosed
• •Biologic therapies, especially anti-CD20 agents, have transformed the standard of care, driving higher average selling prices and longer treatment durations compared with conventional systemic steroids
• •The high unmet clinical need, given the life-threatening severity of untreated PV and the toxicity profile of existing steroid-based regimens, supports strong demand for novel, safer therapeutic alternatives

The PV therapeutics market is typically segmented by drug class, with conventional systemic corticosteroids and immunosuppressants (such as azathioprine and mycophenolate mofetil) comprising the largest volume segment, while biologics, particularly anti-CD20 monoclonal antibodies, represent the fastest-growing value segment. Route-of-administration splits between intravenous, oral, and topical formulations, with IV biologics commanding premium pricing. Geographically, North America leads in revenue contribution due to higher diagnosis rates, favorable reimbursement, and earlier adoption of biologic therapies.

• •North America and Western Europe together account for the majority of current market revenue, supported by advanced healthcare infrastructure and higher disease prevalence awareness
• •Asia-Pacific is the fastest-growing regional segment, driven by rising healthcare expenditure, improving diagnostic access, and growing recognition of autoimmune dermatological conditions
• •By drug class, the market splits between corticosteroids/immunosuppressants (volume-driven) and biologics/targeted therapies (value-driven), with the latter gaining share as clinical evidence accumulates

Who are the notable companies in the industry?

The pemphigus vulgaris therapeutics market is moderately to highly consolidated, dominated by a small number of large multinational pharmaceutical firms with established biologic manufacturing capabilities and extensive dermatology/immunology portfolios. These players are primarily integrated producers, spanning active pharmaceutical ingredient (API) synthesis, formulation, and global commercialization, rather than specialty niche manufacturers. Regional capacity is concentrated in North America and Western Europe, where most approved biologic therapies are manufactured, with emerging-market participation largely limited to generic immunosuppressant production and import-dependent biologic distribution.

• •The market exhibits moderate consolidation, with a handful of large integrated pharmaceutical companies controlling biologic supply chains and holding the majority of branded therapy revenues
• •Manufacturing is split between conventional chemical synthesis routes for small-molecule corticosteroids and immunosuppressants, and complex biologics production (cell-culture-based monoclonal antibody manufacturing) concentrated in OECD-region facilities
• •Regional production capacity is heavily skewed toward North America and Western Europe for biologics, while Asia-Pacific capacity is predominantly focused on generic immunosuppressants and biosimilar development

What are the recent trends and outlook?

The market trajectory points toward increasing biologics penetration, as clinical data continue to demonstrate superior efficacy and safety profiles for targeted therapies over long-term systemic steroid use. Emerging treatment modalities, including novel monoclonal antibodies targeting additional immune pathways, IgG-specific enzymatic inhibitors, and cell-based regenerative approaches, are advancing through clinical development and could reshape the competitive picture by the early 2030s. Combination therapy strategies and patient-tailored treatment protocols based on disease severity biomarkers are also gaining clinical traction, supporting the broader trend toward personalized medicine in autoimmune dermatology.

• •Biologic and targeted therapies are projected to increase their share of total market value over conventional treatments, as payers and clinicians seek steroid-sparing alternatives with improved long-term safety profiles
• •Clinical pipelines include agents targeting novel pathways such as IL-5, neonatal Fc receptor (FcRn) inhibition, and B-cell subsets beyond CD20, which could expand the addressable patient population
• •The market is broadly expected to surpass USD 1 billion by the early 2030s, with sustained growth supported by pipeline approvals, geographic expansion of diagnosis and treatment access, and rising autoimmune disease incidence